Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs
详细信息 查看全文
- 作者：Peter Fraunberger ; Elisabeth Gröne ; Hermann-Josef Gröne…
- 关键词：Inflammation ; Cholesterol ; Ezetimibe ; Guinea pigs ; Liver ; Intestine
- 刊名：Journal of Inflammation
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：14
- 期：1
- 全文大小：3795KB
- 刊物主题：Immunology; Allergology; Cytokines and Growth Factors; Rheumatology; Pharmacology/Toxicology; Gastroenterology;
- 出版者：BioMed Central
- ISSN：1476-9255
- 卷排序：14
文摘
BackgroundStatins (HMG CoA reductase inhibitors), in addition to reducing circulating cholesterol and incidence of coronary heart disease, also have pleiotropic, anti-inflammatory effects. Patients with chronic liver diseases, non-alcoholic fatty liver disease (NAFLD) or hepatitis C are often excluded from statin therapy because of adverse effects in a small cohort of patients despite increased cardiovascular risk cholesterol. Ezetimibe, which inhibits cholesterol absorption by inhibition of Niemann-Pick C1 like 1 (NPC1L1) protein in the brush border of intestinal cells, has been suggested as a new therapeutic option in these patients.